Literature DB >> 10840138

Neuropeptide Y in brains of the Flinders Sensitive Line rat, a model of depression. Effects of electroconvulsive stimuli and d-amphetamine on peptide concentrations and locomotion.

P A Jiménez Vasquez1, P Salmi, S Ahlenius, A A Mathé.   

Abstract

Neuropeptide Y (NPY), has been implicated in the pathophysiology of depression and the mechanisms of action of electroconvulsive treatment (ECT). In this series of experiments, we explored whether there are differences between Flinders Sensitive Line (FSL) rats, an animal model of depression, and controls, Flinders Resistant Line (FRL) in (1) baseline brain NPY-LI concentrations, (2) effects of ECS on locomotion and brain neuropeptides, (3) amphetamine effects on behavior, and (4) effects of ECS pretreatment on subsequent effects of amphetamine on behavior. Both strains were divided into two groups, receiving eight ECS or ShamECS. Twenty-four hours after the last session, animals were habituated in activity boxes for 45 min before given d-amphetamine (1.5 mg.kg(-1), subcutaneously) or vehicle. Locomotor activity was then recorded for an additional 45 min. Twenty-four hours later, rats were sacrificed by microwave irradiation, the brains dissected into frontal cortex, occipital cortex, hippocampus, hypothalamus and striatum, and the neuropeptides extracted and measured by radioimmunoassay. No differences between FSL and FRL rats in baseline locomotor activity were found. FSL compared to FRL animals showed a significantly larger locomotion increase following saline and a significantly smaller increase following amphetamine. ECS pretreatment significantly decreased the saline effects on locomotion in the FSL and the amphetamine effects in the FRL rats. 'Baseline' NPY-like immunoreactivity (LI) concentrations were lower in the hippocampus of the 'depressed' rats. ECS increased NPY-LI in frontal cortex, occipital cortex and hippocampus of both strains. The hippocampal NPY-LI increase was significantly larger in the FSL compared to FRL animals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10840138     DOI: 10.1016/s0166-4328(00)00142-x

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  11 in total

1.  Neuropeptide expression in rats exposed to chronic mild stresses.

Authors:  Valeriy Sergeyev; Serguei Fetissov; Aleksander A Mathé; Patricia A Jimenez; Tamas Bartfai; Patrick Mortas; Laurent Gaudet; Jean-Luc Moreau; Tomas Hökfelt
Journal:  Psychopharmacology (Berl)       Date:  2004-10-30       Impact factor: 4.530

2.  Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response.

Authors:  Georg Nikisch; Aleksander A Mathé; Adelheid Czernik; Jutta Thiele; Jürgen Bohner; Chin B Eap; Hans Agren; Pierre Baumann
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

3.  Both acute and chronic buspirone treatments have different effects on regional 5-HT synthesis in Flinders Sensitive Line rats (a rat model of depression) than in control rats.

Authors:  Kyoko Nishi; Kazuya Kanemaru; Shu Hasegawa; Arata Watanabe; Mirko Diksic
Journal:  Neurochem Int       Date:  2008-11-25       Impact factor: 3.921

Review 4.  Depression and antidepressants: molecular and cellular aspects.

Authors:  Cristina Lanni; Stefano Govoni; Adele Lucchelli; Cinzia Boselli
Journal:  Cell Mol Life Sci       Date:  2009-06-12       Impact factor: 9.261

5.  Allele-specific programming of Npy and epigenetic effects of physical activity in a genetic model of depression.

Authors:  P A Melas; A Lennartsson; H Vakifahmetoglu-Norberg; Y Wei; E Åberg; M Werme; M Rogdaki; M Mannervik; G Wegener; S Brené; A A Mathé; C Lavebratt
Journal:  Transl Psychiatry       Date:  2013-05-07       Impact factor: 6.222

6.  Targeting the Neuropeptide Y System in Stress-related Psychiatric Disorders.

Authors:  Nicole M Enman; Esther L Sabban; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Neurobiol Stress       Date:  2015-01-01

7.  Cerebrospinal fluid neuropeptide Y levels in major depression and reported childhood trauma.

Authors:  Laili Soleimani; Maria A Oquendo; Gregory M Sullivan; Aleksander A Mathé; J John Mann
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

8.  Antidepressant-like activity of the neuropeptide Y Y5 receptor antagonist Lu AA33810: behavioral, molecular, and immunohistochemical evidence.

Authors:  Helena Domin; Bernadeta Szewczyk; Bartłomiej Pochwat; Monika Woźniak; Maria Śmiałowska
Journal:  Psychopharmacology (Berl)       Date:  2016-12-14       Impact factor: 4.530

Review 9.  Neuropeptide Y in Alcohol Addiction and Affective Disorders.

Authors:  Annika Thorsell; Aleksander A Mathé
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-31       Impact factor: 5.555

Review 10.  Relaxin' the brain: a case for targeting the nucleus incertus network and relaxin-3/RXFP3 system in neuropsychiatric disorders.

Authors:  Jigna Rajesh Kumar; Ramamoorthy Rajkumar; Tharindunee Jayakody; Subhi Marwari; Jia Mei Hong; Sherie Ma; Andrew L Gundlach; Mitchell K P Lai; Gavin S Dawe
Journal:  Br J Pharmacol       Date:  2016-09-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.